Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–40 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Weight-Related Comorbidity Clear all
Completed Phase 2 Interventional Results available

A Study of LY3502970 in Participants With Obesity or Overweight With Weight-related Comorbidities

NCT05051579
View directory record Official record
Conditions
Obesity, Overweight and Obesity
Interventions
LY3502970, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
18
States / cities
Anaheim, California • Concord, California • Greenbrae, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 28, 2026, 2:14 PM EDT
Recruiting Not applicable Interventional

Lean Beef as Part of a Healthy Meal Plan in Adolescents With Polycystic Ovary Syndrome (PCOS)/Polyendocrine Metabolic Ovarian Syndrome (PMOS)

NCT07780188
View directory record Official record
Conditions
PCOS (Polycystic Ovary Syndrome), Obese Adolescents, Overweight (Without Type 2 Diabetes) With Weight-related Comorbidities, Overweight Adolescents, Irregular Menstrual Cycle, Irregular Menstrual Cycles, Hirsutism, Hyperandrogenism
Interventions
Beef+
Other
Lead sponsor
Texas A&M University
Other
Eligibility
11 Years to 17 Years · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
College Station, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Terminated Not applicable Interventional Results available

The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality

NCT00487162
View directory record Official record
Conditions
Hyperglycemia
Interventions
intensive glycemic control, conventional glycemic control
Procedure · Drug
Lead sponsor
University of Medicine and Dentistry of New Jersey
Other
Eligibility
18 Years to 95 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities

NCT06277934
View directory record Official record
Conditions
Obesity
Interventions
RGT001-075, Placebo
Drug
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Los Angeles, California • Valparaiso, Indiana • Omaha, Nebraska + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06693843
View directory record Official record
Conditions
Obesity, Overweight, or Chronic Weight Management
Interventions
Aleniglipron or Placebo, Aleniglipron
Drug
Lead sponsor
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
18 Years to 79 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
39
States / cities
Phoenix, Arizona • Anaheim, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Recruiting Phase 2 Interventional

Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus

NCT07282743
View directory record Official record
Conditions
Type II Diabetes Mellitus
Interventions
GL0034 Dose Level 1, GL0034 Dose Level 2, GL0034 Dose Level 3, GL0034 Dose Level 4, GL0034 Dose Level 5, GL0034 Dose Level 6, Placebo
Drug · Other
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
9
States / cities
Little Rock, Arkansas • Hialeah Gardens, Florida • Lakeland, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity

NCT06965413
View directory record Official record
Conditions
Obesity, Overweight, Overweight With One Weight Related Comorbidity
Interventions
RO7204239, RO7204239 Matching Placebo, Tirzepatide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Anniston, Alabama • Spring Valley, California • Clermont, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Psychological Treatment of Overweight Binge Eaters

NCT01208272
View directory record Official record
Conditions
Binge Eating Disorder, Cognitive Therapy/Methods, Mental Disorders/Epidemiology, Obesity/Epidemiology, Obesity/Therapy
Interventions
Cognitive Behavioral Therapy (CBT), Interpersonal Therapy (IPT)
Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1994 – 1999
U.S. locations
2
States / cities
New Haaven, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 22, 2010 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 3 Interventional

A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT06047548
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
441 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
20
States / cities
Pelham, Alabama • Los Angeles, California • Santa Ana, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

NCT04184622
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Tirzepatide, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
2,539 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
54
States / cities
Pelham, Alabama • Scottsdale, Arizona • Concord, California + 47 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions

NCT06867718
View directory record Official record
Conditions
Obesity or Overweight
Interventions
RGT001-075, Placebo Comparator
Drug
Lead sponsor
Regor Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
35
States / cities
Mobile, Alabama • Phoenix, Arizona • Huntington Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875
View directory record Official record
Conditions
Obesity, Overweight
Interventions
Ribupatide, Placebo
Drug
Lead sponsor
Kailera
Industry
Eligibility
18 Years and older
Enrollment
2,340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
24
States / cities
Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

NCT07553299
View directory record Official record
Conditions
Obesity, Overweight, Weight Maintenance
Interventions
VRB-101, Placebo
Drug
Lead sponsor
Verdiva Bio Dev Limited
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
20
States / cities
Cullman, Alabama • Phoenix, Arizona • Tempe, Arizona + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3437943 in Participants Who Have Obesity or Are Overweight

NCT04881760
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3437943, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
25
States / cities
Scottsdale, Arizona • Anaheim, California • Fresno, California + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 28, 2026, 2:14 PM EDT
Completed Phase 2 Interventional

A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity

NCT06595238
View directory record Official record
Conditions
Obesity or Overweight
Interventions
AZD6234, Placebo comparator
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
262 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
23
States / cities
Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 28, 2026, 2:14 PM EDT
Not yet recruiting Not applicable Interventional

ENLIGHT Trial: ESG With Fundal Mucosal Ablation

NCT07792226
View directory record Official record
Conditions
Obesity, Obesity (Body Mass Index >30 kg/m2)
Interventions
Endoscopic Sleeve Gastroplasty (ESG), Fundal Mucosal Ablation
Procedure
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 28, 2026, 2:14 PM EDT